Format

Send to

Choose Destination
Nat Rev Immunol. 2014 Sep;14(9):585-600. doi: 10.1038/nri3707.

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.

Author information

1
Division of Rheumatology and Clinical Immunology, S702 BST, 3500 Terrace Street, Pittsburgh, Pennsylvania 15261, USA.
2
Merck Research Laboratories, Palo Alto, 901 California Avenue, Palo Alto, California 94304, USA.

Abstract

Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major revision of the TH subset paradigm and substantial progress has been made in deciphering the molecular mechanisms of T cell lineage commitment and function. In this Review, we focus on the recent advances that have been made regarding the transcriptional control of TH17 cell plasticity and stability, as well as the effector functions of TH17 cells, and we highlight the mechanisms of IL-17 signalling in mesenchymal and barrier epithelial tissues. We also discuss the emerging clinical data showing that IL-17-specific and IL-23-specific antibody treatments are remarkably effective for treating many immune-mediated inflammatory diseases.

PMID:
25145755
PMCID:
PMC4281037
DOI:
10.1038/nri3707
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center